Drugs and Women's Health, Ema Prepares a Roadmap to Fill Gaps in Research
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
The European Medicines Agency (EMA) has reported that, by the end of 2026, it will develop a regulatory roadmap to drive a decisive change in the way women's health is considered in the development and regulation of medicines, so that they are represented in clinical trials and drug development.
The European Medicines Agency’s 10 priority actions to drive significant changes in both pharmaceutical research and women’s health By the end of 2026, the European Medicines Agency (EMA) will develop a regulatory roadmap to drive decisive changes in the way women’s health is taken into account in the development and regulatory assessment of medicines. This initiative follows a multi-stakeholder workshop held on 28 and 29 September in Amsterdam,…
The European Medicines Agency aims to strengthen the presence of women in clinical trials and the production of data broken down by sex. By the end of 2026 a roadmap will be defined with short, medium and long-term actions. Among the priorities also the inclusion of women in pregnancy and lactation and increased use of real-world data. The post Medicines and women's health, the Ema prepares a roadmap to fill gaps in research appeared first on Da…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
